![Cerebrolysin injections 20 ml - [5 ampoules]](https://mediscom.com.co/wp-content/uploads/2022/11/Cerebrolysin-20ml-5.webp "Cerebrolysin-20ml-5.webp")
Description
Cerebrolysin Pharmacodynamics
Cerebrolysin contains low molecular weight biologically active neuropeptides, which penetrate through the blood-brain barrier and directly reach the nerve cells. The drug has an organ-specific multimodal effect on the brain, i.e. it provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.
a) metabolic regulation: cerebrolysine increases the efficiency of aerobic energy metabolism of the brain, improves intracellular protein synthesis in the developing and aging brain.
b) Neuroprotection: cerebrolysine protects neurons from the damaging effects of lactacidosis, prevents the formation of free radicals, increases survival and prevents the death of neurons in conditions of hypoxia and ischemia, reduces the damaging neurotoxic effects of excitatory amino acids (glutamate).
c) Neurotrophic activity: cerebrolysine is the only nootropic peptidergic drug with proven neurotrophic activity, similar to the action of natural neural growth factors (NGF), but manifested under conditions of peripheral administration.
d) functional neuromodulation: cerebrolysin has a positive effect on cognitive disorders and memory processes.
Indications
Alzheimer’s disease, syndrome of a dementia of various genesis, chronic cerebrovascular insufficiency, an ischemic stroke, traumatic damages of brain and a spinal cord; mental retardation at children, hyperactivity and attention deficiency at children; in complex therapy – at the endogenous depression, resistant to antidepressants
Contraindications
-individual intolerance to Cerebrolysin injections
-severe renal insufficiency
-epileptic status
Caution: use Cerebrolysin injections in case of allergic diathesis, diseases of epileptic character, including generalized epilepsy, due to possible increase in seizure frequency.
ADMINISTRATION DURING PREGNANCY AND LACTATION
During pregnancy and during breastfeeding, Cerebrolysin injections should be used only after careful analysis of the ratio of the positive effect of treatment to the risk associated with it. The results of experimental studies do not suggest that Cerebrolysin has any teratogenic effect or has a toxic effect on the fetus. However, similar clinical studies have not been conducted.
Dosage and administration
- It is administered parenterally. Doses and duration of treatment depend on the nature and severity of the disease, as well as the age of the patient. Single doses up to 50 ml can be administered, but treatment course is more preferable.
- The recommended optimal course of treatment is daily injections for 10-20 days.
- Acute conditions (ischemic stroke, craniocerebral injury, complications of neurosurgical operations): 10 ml to 50 ml
- In the residual period of cerebral stroke and traumatic brain and spinal cord injury: 5 ml to 50 ml.
- For psycho-organic syndrome and depression: 5 ml to 30 ml.
- For Alzheimer’s disease, vascular and mixed Alzheimer’s disease and vascular dementia: 5 ml to 30 ml
- In neuropediatric practice: 0.1 to 0.2 ml/kg body weight
- To increase the effectiveness of treatment, repeated courses may be given as long as improvement in the patient’s condition due to treatment is observed.
- After the first course, the frequency of dosing may be reduced to 2 or 3 times per week.
- Cerebrolysin is administered as injections: intramuscularly (up to 5 ml) and intravenously (up to 10 ml).
- Doses from 10 ml to 50 ml are recommended to be administered only by slow intravenous infusions after dilution with the suggested standard solutions for infusion.
- The duration of infusion is 15 to 60 minutes.
